Apogee Therapeutics Files 8-K for Financials and Exhibits

Ticker: APGE · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1974640

Apogee Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyApogee Therapeutics, Inc. (APGE)
Form Type8-K
Filed DateMar 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.00001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, exhibits, sec-filing

Related Tickers: APGE

TL;DR

APGE filed an 8-K for routine financial disclosures. Nothing major to see here.

AI Summary

On March 5, 2024, Apogee Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures rather than a specific material event. The company, incorporated in Delaware, is involved in the biological products sector.

Why It Matters

This 8-K filing serves as a standard disclosure for Apogee Therapeutics, Inc., providing investors with updated financial information and exhibits as required by the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any significant new risks or events.

Key Players & Entities

  • Apogee Therapeutics, Inc. (company) — Registrant
  • March 5, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, 02453 (address) — Principal Executive Offices
  • 650-394-5230 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for Apogee Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on March 5, 2024.

In which state is Apogee Therapeutics, Inc. incorporated?

Apogee Therapeutics, Inc. is incorporated in Delaware.

What is the business address of Apogee Therapeutics, Inc.?

The business address of Apogee Therapeutics, Inc. is 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, 02453.

What is the SIC code for Apogee Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Apogee Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-03-05 08:15:42

Key Financial Figures

  • $0.00001 — ch registered Common Stock, par value $0.00001 per share APGE The Nasdaq Global Ma

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On March 5, 2024, Apogee Therapeutics, Inc. (the "Company") made available a presentation regarding its initial Phase 1 data from its first-in-human study of APG777 on the Company's website. A copy of the data presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . EXHIBIT INDEX Exhibit No. Description 99.1 Data Presentation, dated March 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apogee Therapeutics, Inc. Date: March 5, 2024 By: /s/ Michael Henderson, M.D. Michael Henderson, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.